KTRA cotización, noticias, gráficos, investigación bursátil, perfil.

 (KTRA) Bolsa Cotizaciones y resumen de noticias

Kintara Therapeutics

Goldman Sachs analyst Eric Sheridan downgrades Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Buy to Neutral and lowers the price target from $3.25 to $2.5.

News

Downgrades

Price Target

Analyst Ratings

ANGI

Goldman Sachs Downgrades Angi to Neutral, Lowers Price Target to $2.5

Trading Ideas

MTEM

Molecular Templates Shares Resume Trade Following Circuit Breaker Halt

ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shared its strategic roadmap during the 2024 Investor Day, highlighting key growth drivers and market expectations through <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41962514/asml-provides-updated-view-on-market-opportunities-at-2024-investor-day-meeting" rel="noreferrer noopener">the decade&#8217;s end</a>.
The semiconductor equipment maker projected significant revenue expansion, with scenarios estimating annual sales of $46.51 billion &#8211; $63.43 billion (44 billion euros &#8211; 60 billion euros) by 2030, alongside a gross margin target of 56%-60%.
CEO Christophe Fouquet sees the company&#8217;s extended lithography portfolio and scalable EUV (Extreme Ultraviolet) technology as crucial assets in capturing the potential of these emerging opportunities.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/24/11/41951575/taiwan-semi-boosts-advanced-chipmaking-with-record-euv-expansion-grabs-56-global-share" rel="noreferrer noopener">Taiwan Semi Boosts Advanced Chipmaking with Record EUV Expansion, Grabs 56% Global Share</a>
ASML expects robust demand from the semiconductor sector, with projected global sales surpassing $1 trillion by 2030.
This outlook translates to an annual market growth rate of around 9% from 2025 to 2030. The firm anticipates a double-digit CAGR for EUV lithography spending within the same period, focusing on advanced Logic and DRAM nodes.
According to ASML, the integration of AI across industries presents a substantial opportunity for semiconductor firms. The company plans to leverage its EUV capabilities to accommodate the rising need for high-performance chips used in AI applications.
The scalability of EUV technology allows for efficient multi-patterning, which ASML expects will drive greater customer adoption through cost-effective manufacturing processes.
ASML&#8217;s CFO, Roger Dassen, highlighted the company&#8217;s confidence in its financial targets, citing a strong pipeline of product demand and increasing lithography spending.
He restated the company&#8217;s capital allocation strategy, which includes substantial returns to shareholders through dividends and share buybacks.
The company is navigating geopolitical tensions between Washington and China as a U.S. ally.
ASML CEO Christophe Fouquet acknowledges <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41876507/asmls-it-outage-affected-chipmaking-operations-worldwide" rel="noreferrer noopener">rising U.S. pressure</a> to restrict chip technology sales to China. Despite this, China remains ASML&#8217;s top market, primarily for sales of mature chips rather than the advanced AI semiconductors targeted by U.S. export restrictions.
ASML dominates the market for specialized lithography machines, essential for companies like Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) in producing cutting-edge chips used in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) smartphones and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) AI processors.
Reports suggest that Taiwan Semiconductor plans to purchase advanced ASML lithography equipment by the end of the year, with each unit priced at $350 million.
Price Actions:&nbsp;ASML stock traded higher by 5.09% at $707.67 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/41977961/mastercards-vision-no-more-passwords-or-card-numbers-by-2030" target="_blank" rel="noreferrer noopener">Mastercard&#8217;s 2030 Vision: A Future Without Passwords, Card Numbers</a></li>
</ul>
Photo via ASML

Tech

AAPL

ASML

NVDA

ASML Projects Revenue Surge to $63 Billion by 2030, Eyes AI and Chip Market Boom

Canaccord Genuity analyst Kyle Mikson maintains Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and maintains $3 price target.

LUCD

Canaccord Genuity Maintains Buy on Lucid Diagnostics, Maintains $3 Price Target

Canaccord Genuity analyst Caitlin Cronin maintains KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) with a Buy and raises the price target from $3 to $4.

KRMD

Canaccord Genuity Maintains Buy on KORU Medical Systems, Raises Price Target to $4

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories A Draw Of 4.407M Barrels Vs A Build Of 1.000M Barrels Est.; Build Of 0.412M Prior

BMO Capital analyst Tamy Chen maintains Martinrea International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MRE#TSX">MRE</a>) with a Outperform and lowers the price target from C$15 to C$13.

TSX:MRE

BMO Capital Maintains Outperform on Martinrea International, Lowers Price Target to C$13

EIA Weekly Distillates Stocks A Draw Of 1.394M Barrels Vs A Build Of 1.000M Barrels Est.; Build Of 2.947M Barrels Prior

Canaccord Genuity analyst Joseph Vafi maintains HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Buy and raises the price target from $6 to $7.

HIVE

Canaccord Genuity Maintains Buy on HIVE Digital Technologies, Raises Price Target to $7

USA Crude Oil Inventories A Build Of 2.089M Barrels Vs A Build Of 0.400M Barrels Est.; Build Of 2.149M Barrels Prior

RBC Capital analyst Greg Pardy maintains Suncor Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SU#TSX">SU</a>) with a Outperform and raises the price target from C$64 to C$66.

TSX:SU

RBC Capital Maintains Outperform on Suncor Energy, Raises Price Target to C$66

BMO Capital analyst Devin Dodge maintains Finning International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTT#TSX">FTT</a>) with a Outperform and lowers the price target from C$50 to C$46.

TSX:FTT

BMO Capital Maintains Outperform on Finning International, Lowers Price Target to C$46

Canaccord Genuity analyst George Gianarikas maintains ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) with a Hold and maintains $8 price target.

Canaccord Genuity Maintains Hold on ESS Tech, Maintains $8 Price Target

<a href="https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi" title="https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi">https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi</a>

Biotech

Global

General

BIIB

ESAIY

ESALF

CHMP Recommends EU Approval For Eisai's Leqembi To Treat Early Alzheimer's Disease In Apolipoprotein E ε4 Non-Carriers And Heterozygotes; Leqembi, A Monoclonal Antibody, Shown To Slow Cognitive Decline

BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) with a Outperform and lowers the price target from $28 to $27.

ACRV

BMO Capital Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $27

BMO Capital analyst Tamy Chen maintains AutoCanada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACQ#TSX">ACQ</a>) with a Market Perform and lowers the price target from C$19.5 to C$19.

TSX:ACQ

BMO Capital Maintains Market Perform on AutoCanada, Lowers Price Target to C$19

Canaccord Genuity analyst Kingsley Crane maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and raises the price target from $310 to $330.

CYBR

Canaccord Genuity Maintains Buy on CyberArk Software, Raises Price Target to $330

BMO Capital analyst Tom MacKinnon maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Outperform and raises the price target from C$88 to C$92.

TSX:SLF

BMO Capital Maintains Outperform on Sun Life Financial, Raises Price Target to C$92

Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ross Stores, revealing an average target of $174.75, a high estimate of $190.00, and a low estimate of $152.00. Marking an increase of 4.9%, the current average surpasses the previous average price target of $166.58. 
<img src="https://www.benzinga.com/files/images/story/2024/1731600055_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Ross Stores among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$167.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$162.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ross Stores. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ross Stores compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ross Stores's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ross Stores's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ROST/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ross Stores analyst ratings.</a>
<h2>All You Need to Know About Ross Stores</h2>
Ross Stores operates as an off-price apparel and accessories retailer with the majority of its sales derived from its Ross Dress for Less banner. The firm opportunistically procures excess brand-name merchandise made available via manufacturing overruns and retail liquidation sales at a 20%-60% discount to full prices. As such, its stores are often filled with a vast array of stock-keeping units, each with minimal product depth that creates a treasure hunt shopping experience. The firm's more than 1,750 Ross Dress for Less stores are primarily located in densely populated suburban communities and typically serve middle-income consumers. Ross also operates about 350 DD's Discounts chains targeting lower-income shoppers.
<h3>Understanding the Numbers: Ross Stores's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Ross Stores's remarkable performance in 3 months is evident. As of 31 July, 2024, the company achieved an impressive revenue growth rate of 7.15%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.97%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ross Stores's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.46%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Ross Stores's ROA excels beyond industry benchmarks, reaching 3.61%. This signifies efficient management of assets and strong financial health.
Debt Management: Ross Stores's debt-to-equity ratio is below the industry average. With a ratio of 1.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ROST

Forecasting The Future: 12 Analyst Projections For Ross Stores

Ratings for TechTarget (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTGT#NASDAQ">TTGT</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for TechTarget, revealing an average target of $38.6, a high estimate of $40.00, and a low estimate of $36.00. This current average represents a 2.53% decrease from the previous average price target of $39.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1731600045_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive TechTarget. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jason Kreyer</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jason Kreyer</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TechTarget. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TechTarget compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for TechTarget's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into TechTarget's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TTGT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TechTarget analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About TechTarget</h2>
TechTarget Inc is a data, software and analytics leader for purchase intent-driven marketing and sales data which delivers business impact for business-to-business (B2B) companies. The company solutions are designed to enable B2B technology companies to identify, reach, and influence key enterprise technology decision makers faster and with higher efficacy. Geographically, it derives a majority of its revenue from North America. Its products and services intended to improve information technology vendors abilities to impact targeted audiences for business growth using targeting, first-party analytics and data services complemented with customized marketing programs that integrate content creation, demand generation, brand marketing, and other advertising techniques.
<h3>TechTarget's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining TechTarget's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.83% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.23%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): TechTarget's ROE stands out, surpassing industry averages. With an impressive ROE of 0.57%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): TechTarget's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.18%, the company showcases efficient use of assets and strong financial health.
Debt Management: TechTarget's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.82, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TTGT

The Analyst Landscape: 5 Takes On TechTarget

Kintara Therapeutics ( ($KTRA) ) just unveiled an update. Kintara Therapeutics, Inc. has provided updates on its corporate progress and the REM-001...

Kintara Therapeutics Advances with TuHURA Merger and Trials

Kintara Therapeutics ( ($KTRA) ) has provided an announcement. Kintara Therapeutics, Inc. is urging stockholders to vote on a crucial merger with T...

Kintara Therapeutics Seeks Approval for Key Merger with TuHURA Biosciences

Kintara Therapeutics ( ($KTRA) ) has issued an update. Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. have announced their upcoming Specia...

Kintara Announces Special Meeting for Proposed TuHURA Merger

Kintara Therapeutics (KTRA) has released an update. Kintara Therapeutics has postponed its Special Meeting of Stockholders to October 4, 2024, due ...

Kintara Postpones Stockholder Meeting for Merger Decision

Kintara Therapeutics ( ($KTRA) ) has issued an announcement. Kintara Therapeutics, Inc. is urging its stockholders to vote on crucial proposals tha...

Kintara Urges Shareholder Votes for TuHURA Biosciences Merger

The latest update is out from Kintara Therapeutics ( ($KTRA) ). Kintara Therapeutics has announced its fiscal 2024 financial results, revealing a n...

Kintara Therapeutics Reveals Improved Financials, Merger Plans

Kintara Therapeutics (KTRA) has released an update. Kintara Therapeutics is set to merge with TuHURA Biosciences, aiming to close the deal on Octob...

Kintara Therapeutics Set for Strategic Merger and CVR Issuance

Kintara stock climbs 10% on TuHURA merger update

Kintara Therapeutics (KTRA) has released an update. Kintara Therapeutics has corrected its previous announcement regarding the issuance of Continge...

Kintara Therapeutics Updates on Merger and CVR Issuance

Kintara Therapeutics (KTRA) has released an update. Kintara Therapeutics announced a reverse stock split at a 1-for-35 ratio, set to take effect on...

Kintara Therapeutics Announces Stock Split Amid Merger

KTRA

Press Releases

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Earnings

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Stock Split

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

AMGEN

BMRN

RHHBY

TSX:RKV

TSXV:RKV

XBIT

Maxim Group

HC Wainwright & Co.

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Looking to invest in crypto? Discover the best crypto to invest in with our guide, featuring top picks and expert insights to maximize your returns.

10 Best Cryptocurrencies to Invest In for November 2024

10 Best Cryptocurrencies to Invest in for November 2024

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Cannabis

Cryptocurrency

Politics

Exclusives

Interview

EXCLUSIVE: Chris Christie Says Trump Will Remove Federal Restrictions On Marijuana, Find 'Sweet Spot' For Crypto Regulation (UPDATED)

Education

$PEPE

COIN

HOOD

If You Invested $100 In Pepe Coin At Launch, Here's How Much You'd Have Today

$BTC

$DOGE

If You Invested $100 In Dogecoin When The Meme Coin Launched, Here's How Much You'd Have Today

Markets

TSLA

Elizabeth Warren's Sarcastic Take On DOGE's Split Leadership Gets Slammed By Elon Musk: 'Unlike You, Neither Of Us Are Being Paid'

Trump's Attorney General Pick Matt Gaetz Once Proposed Collecting Federal Income Taxes In Bitcoin, Apart From Co-sponsoring Bill To Abolish The Fed

Apertura	-
Cierre	-
Volumen / Prom.	- / -
Rango diario	- - -
Rango de 52 semanas	- - -
Capitalización bursátil	-
Ratio PER	-
Rentabilidad por dividendo	-
Exchange
RSI	0
Interés en corto	-
Días para cubrir	1.98

Apertura	-
Cierre	-
Volumen / Prom.	- / -
Rango diario	- - -
Rango de 52 semanas	- - -
Capitalización bursátil	-
Ratio PER	-
Rentabilidad por dividendo	-
Exchange
RSI	0
Interés en corto	-
Días para cubrir	1.98

Comments

(KTRA) Previsión

(KTRA) Bolsa Cotizaciones y resumen de noticias

Noticias recientes

Finanzas

Calificación de analistas

Comparar

PREGUNTAS FRECUENTES

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Nombre

Ingresos Variación
Bruto Variación
EBITDA Variación
EBIT Variación
Beneficios Variación